KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Change in Cash (2016 - 2025)

Opko Health (OPK) has disclosed Change in Cash for 16 consecutive years, with -$46.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 280.56% year-over-year to -$46.1 million, compared with a TTM value of -$62.9 million through Dec 2025, down 117.98%, and an annual FY2025 reading of -$62.9 million, down 117.98% over the prior year.
  • Change in Cash was -$46.1 million for Q4 2025 at Opko Health, down from $143.5 million in the prior quarter.
  • Across five years, Change in Cash topped out at $379.5 million in Q3 2024 and bottomed at -$164.3 million in Q2 2025.
  • Average Change in Cash over 5 years is $15.5 million, with a median of -$17.1 million recorded in 2021.
  • Peak annual rise in Change in Cash hit 1143.7% in 2024, while the deepest fall reached 1188.13% in 2024.
  • Year by year, Change in Cash stood at -$13.9 million in 2021, then tumbled by 99.06% to -$27.6 million in 2022, then tumbled by 54.59% to -$42.7 million in 2023, then surged by 159.78% to $25.5 million in 2024, then crashed by 280.56% to -$46.1 million in 2025.
  • Business Quant data shows Change in Cash for OPK at -$46.1 million in Q4 2025, $143.5 million in Q3 2025, and -$164.3 million in Q2 2025.